Cancer Genetics Inc  

(Public, NASDAQ:CGIX)   Watch this stock  
Find more results for FRANKLYN G. PRENDERGAST
10.65
-0.03 (-0.28%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.48 - 10.76
52 week 8.48 - 23.25
Open 10.74
Vol / Avg. 23,144.00/54,485.00
Mkt cap 98.86M
P/E     -
Div/yield     -
EPS -3.47
Shares 9.28M
Beta     -
Inst. own 42%
May 15, 2014
Q1 2014 Cancer Genetics Inc Earnings Release
May 15, 2014
Q1 2014 Cancer Genetics Inc Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -173.79% -187.18%
Operating margin -275.23% -128.01%
EBITD margin - -123.07%
Return on average assets -18.42% -38.60%
Return on average equity -22.38% -115.19%
Employees 61 -
CDP Score - -

Address

2ND FLOOR, 201 ROUTE 17 NORTH
RUTHERFORD, NJ 07070
United States - Map
+1-201-5289200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cancer Genetics, Inc. (CGI) is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.

Officers and directors

John G. Pappajohn Chairman of the Board
Age: 85
Bio & Compensation  - Reuters
Panna L. Sharma President, Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Edward J. Sitar CPA Chief Financial Officer, Treasurer, Secretary
Age: 53
Bio & Compensation  - Reuters
Jane Houldsworth Ph.D. Vice President - Research & Development
Age: 55
Bio & Compensation  - Reuters
Raju S. K. Chaganti Ph.D. Director
Age: 81
Bio & Compensation  - Reuters
Keith L. Brownlie CPA Independent Director
Age: 61
Bio & Compensation  - Reuters
Edmund M. Cannon Independent Director
Age: 69
Bio & Compensation  - Reuters
Franklyn G. Prendergast M.D., Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Paul Rothman M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters